FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037177568> ?p ?o ?g. }

• W2037177568 endingPage "1844" @default.
• W2037177568 startingPage "1830" @default.
• W2037177568 abstract "Introduction:The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non–small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here.Methods:QoL was assessed at baseline and every 3 weeks during first-line, using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and QLQ–lung cancer specific module (LC13). Mean changes from baseline within arms were reported. QoL response and time-to-deterioration of QoL using a competing-risk approach were compared between treatment arms.Results:Six hundred and thirty patients (83%) completed baseline questionnaires. Compliance was affected by differential treatment efficacy, but was similar between arms for patients without progression or death. Significant differences in QoL responses were observed favoring chemotherapy for pain, sleeping, dyspnea, diarrhea, and favoring erlotinib for vomiting, constipation, sore mouth, and alopecia. In the small subset of patients with EGFR-mutated tumors, all selected items (global QoL, physical functioning, cough, dyspnea and pain) improved, whereas worsening or no change was observed in wild-type patients. Improvement was particularly evident in the first-line erlotinib arm as for global QoL and physical functioning.Conclusions:QoL was impacted by differential toxicity and efficacy between arms. Functional domains and global QoL did not differ, although some symptoms were better controlled with chemotherapy in unselected non–small-cell lung cancer patients." @default.
• W2037177568 created "2016-06-24" @default.
• W2037177568 creator A5005815956 @default.
• W2037177568 creator A5007323225 @default.
• W2037177568 creator A5007382846 @default.
• W2037177568 creator A5007575010 @default.
• W2037177568 creator A5007824491 @default.
• W2037177568 creator A5012201620 @default.
• W2037177568 creator A5012567382 @default.
• W2037177568 creator A5012748795 @default.
• W2037177568 creator A5013748999 @default.
• W2037177568 creator A5016655393 @default.
• W2037177568 creator A5017022820 @default.
• W2037177568 creator A5022124014 @default.
• W2037177568 creator A5024690665 @default.
• W2037177568 creator A5025969713 @default.
• W2037177568 creator A5029676357 @default.
• W2037177568 creator A5029922900 @default.
• W2037177568 creator A5031031537 @default.
• W2037177568 creator A5032078755 @default.
• W2037177568 creator A5033620626 @default.
• W2037177568 creator A5034064734 @default.
• W2037177568 creator A5040413764 @default.
• W2037177568 creator A5044346374 @default.
• W2037177568 creator A5045384053 @default.
• W2037177568 creator A5049928688 @default.
• W2037177568 creator A5051933262 @default.
• W2037177568 creator A5055283283 @default.
• W2037177568 creator A5055521763 @default.
• W2037177568 creator A5056034569 @default.
• W2037177568 creator A5073362806 @default.
• W2037177568 date "2012-12-01" @default.
• W2037177568 modified "2023-10-16" @default.
• W2037177568 title "Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer" @default.
• W2037177568 cites W1905936368 @default.
• W2037177568 cites W1947168884 @default.
• W2037177568 cites W2014725195 @default.
• W2037177568 cites W2015409044 @default.
• W2037177568 cites W2019268112 @default.
• W2037177568 cites W2041130945 @default.
• W2037177568 cites W2073140442 @default.
• W2037177568 cites W2106585301 @default.
• W2037177568 cites W2106787323 @default.
• W2037177568 cites W2109567704 @default.
• W2037177568 cites W2111662961 @default.
• W2037177568 cites W2128278369 @default.
• W2037177568 cites W2129360604 @default.
• W2037177568 cites W2132157071 @default.
• W2037177568 cites W2138297714 @default.
• W2037177568 cites W2154662831 @default.
• W2037177568 cites W2160982674 @default.
• W2037177568 cites W2166084034 @default.
• W2037177568 cites W2167571044 @default.
• W2037177568 cites W2169331014 @default.
• W2037177568 cites W2626223149 @default.
• W2037177568 doi "https://doi.org/10.1097/jto.0b013e318275b327" @default.
• W2037177568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23154555" @default.
• W2037177568 hasPublicationYear "2012" @default.
• W2037177568 type Work @default.
• W2037177568 sameAs 2037177568 @default.
• W2037177568 citedByCount "21" @default.
• W2037177568 countsByYear W20371775682013 @default.
• W2037177568 countsByYear W20371775682014 @default.
• W2037177568 countsByYear W20371775682015 @default.
• W2037177568 countsByYear W20371775682016 @default.
• W2037177568 countsByYear W20371775682017 @default.
• W2037177568 countsByYear W20371775682018 @default.
• W2037177568 countsByYear W20371775682019 @default.
• W2037177568 countsByYear W20371775682021 @default.
• W2037177568 countsByYear W20371775682022 @default.
• W2037177568 countsByYear W20371775682023 @default.
• W2037177568 crossrefType "journal-article" @default.
• W2037177568 hasAuthorship W2037177568A5005815956 @default.
• W2037177568 hasAuthorship W2037177568A5007323225 @default.
• W2037177568 hasAuthorship W2037177568A5007382846 @default.
• W2037177568 hasAuthorship W2037177568A5007575010 @default.
• W2037177568 hasAuthorship W2037177568A5007824491 @default.
• W2037177568 hasAuthorship W2037177568A5012201620 @default.
• W2037177568 hasAuthorship W2037177568A5012567382 @default.
• W2037177568 hasAuthorship W2037177568A5012748795 @default.
• W2037177568 hasAuthorship W2037177568A5013748999 @default.
• W2037177568 hasAuthorship W2037177568A5016655393 @default.
• W2037177568 hasAuthorship W2037177568A5017022820 @default.
• W2037177568 hasAuthorship W2037177568A5022124014 @default.
• W2037177568 hasAuthorship W2037177568A5024690665 @default.
• W2037177568 hasAuthorship W2037177568A5025969713 @default.
• W2037177568 hasAuthorship W2037177568A5029676357 @default.
• W2037177568 hasAuthorship W2037177568A5029922900 @default.
• W2037177568 hasAuthorship W2037177568A5031031537 @default.
• W2037177568 hasAuthorship W2037177568A5032078755 @default.
• W2037177568 hasAuthorship W2037177568A5033620626 @default.
• W2037177568 hasAuthorship W2037177568A5034064734 @default.
• W2037177568 hasAuthorship W2037177568A5040413764 @default.
• W2037177568 hasAuthorship W2037177568A5044346374 @default.
• W2037177568 hasAuthorship W2037177568A5045384053 @default.
• W2037177568 hasAuthorship W2037177568A5049928688 @default.
• W2037177568 hasAuthorship W2037177568A5051933262 @default.
• W2037177568 hasAuthorship W2037177568A5055283283 @default.

• next